HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

HUM

Humana Inc. (S&P 500)

Healthcare — Healthcare Plans

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Buy 2.2 / 5 23 analysts
$379.68
$-1.89 (-0.50%)
Target: $423.74 (11.6%)

Price History

52-Week Range
Sign in to add HUM to a watchlist or set price alerts.

Fundamentals

Market Cap$45.59B
P/E Ratio (TTM)36.09
Forward P/E22.88
EPS (TTM)$10.52
Dividend Yield0.93%
Profit Margin0.88%
Revenue Growth26.20%
ROE6.89%
Debt/Equity76.49
Recommendation Buy 2.2
Analyst Target$423.74
Analysts23
Next Earnings Nov 6, 2026 BMO
Indexes S&P 500

Technical Indicators

RSI (14)32.4
Beta0.75
SMA 20$391.11
SMA 40$388.11
52-Week High$428.88
52-Week Low$163.11
50-Day Avg$385.85
200-Day Avg$292.12
Avg Volume$1.22M
Volume891.8K

Performance Analysis

BULLISH

HUM shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 81% of its 52-week range.
~ RSI at 32.4 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
+ Strong revenue growth of 26.2% year-over-year.
+ Wall Street consensus is "Buy" from 23 analysts.
+ Average analyst target of $423.74 implies 11.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:01 UTC

Back to Screener Export Report